ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,516.80
0.39%
S&P ASX All Technology
4,050.50
0.56%
Brent Oil
76.575
-0.08%
US Dollar vs AUD
1.58627
-0.10%
Bitcoin
95,650.13
-0.10%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AnaptysBio Inc (ANAB) Share Price

AnaptysBio Inc

AnaptysBio Inc (ANAB)

NASDAQ
12.375
-0.625
(-4.81%)
Closed 12 February 8:00AM
Delayed by 15 minutes
16.24
3.87
(31.23%)
After Hours: 11:59AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
16.24
Bid
15.12
Offer
16.24
Volume
491,297
12.21 Day's Range 12.99
11.01 52 Week Range 41.3083
Market Cap
494.162M
Previous Close
13.00
Open
12.99
Last Trade
14
@
16
Last Trade Time
Financial Volume
US$ 6,162,500
VWAP
12.5433
Average Volume (3m)
678,308
Shares Outstanding
30,428,682
Dividend Yield
-
PE Ratio
-2.30
Earnings Per Share (EPS)
-5.38
Revenue
17.16M
Net Profit
-163.62M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.anaptysbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was US$13. Over the last year, AnaptysBio shares have traded in a share price range of US$ 11.01 to US$ 41.3083.

AnaptysBio currently has 30,428,682 shares in issue. The market capitalisation of AnaptysBio is US$395.57 million. AnaptysBio has a price to earnings ratio (PE ratio) of -2.30.

Ask ADVFN Intelligence (AI)

AnaptysBio (ANAB) Options Flow Summary

ANAB Options Flow

Overall Flow

Bearish

Net Premium

-2M

Calls / Puts

0.00%

Buys / Sells

450.00%

OTM / ITM

37.50%

Sweeps Ratio

0.00%

ANAB Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
04 February 2025
ANAB (-4.81%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
16 January 2025
ANAB (-4.81%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 January 2025
ANAB (-4.81%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 January 2025
ANAB (-4.81%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 January 2025
ANAB (-4.81%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 January 2025
ANAB (-4.81%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.21-6.934097421217.4517.8111.0174587715.55411484CS
41.479.9526066350714.7718.3411.0169578416.10051423CS
12-2.44-13.062098501118.6826.5111.0167830817.12616489CS
26-16.96-51.084337349433.241.308311.0152518222.69720161CS
52-6.89-29.788153912723.1341.308311.0143289723.70395141CS
156-14.48-47.135416666730.7241.308311.0131630823.03568554CS
2600.724.6391752577315.5241.308311.0131569222.75235521CS

ANAB - Frequently Asked Questions (FAQ)

What is the current AnaptysBio share price?
The current share price of AnaptysBio is US$ 16.24
How many AnaptysBio shares are in issue?
AnaptysBio has 30,428,682 shares in issue
What is the market cap of AnaptysBio?
The market capitalisation of AnaptysBio is USD 395.57M
What is the 1 year trading range for AnaptysBio share price?
AnaptysBio has traded in the range of US$ 11.01 to US$ 41.3083 during the past year
What is the PE ratio of AnaptysBio?
The price to earnings ratio of AnaptysBio is -2.3
What is the cash to sales ratio of AnaptysBio?
The cash to sales ratio of AnaptysBio is 21.94
What is the reporting currency for AnaptysBio?
AnaptysBio reports financial results in USD
What is the latest annual turnover for AnaptysBio?
The latest annual turnover of AnaptysBio is USD 17.16M
What is the latest annual profit for AnaptysBio?
The latest annual profit of AnaptysBio is USD -163.62M
What is the registered address of AnaptysBio?
The registered address for AnaptysBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the AnaptysBio website address?
The website address for AnaptysBio is www.anaptysbio.com
Which industry sector does AnaptysBio operate in?
AnaptysBio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AIFFFirefly Neuroscience Inc
US$ 8.34
(169.03%)
195.41M
SOPASociety Pass Inc
US$ 5.70
(119.23%)
52.99M
OMGAOmega Therapeutics Inc
US$ 0.1916
(77.41%)
319.92M
LTRYLottery com Inc
US$ 2.19
(76.61%)
56.53M
SHOTWSafety Shot Inc
US$ 0.1866
(58.81%)
2.82k
FTELFitell Corporation
US$ 1.00
(-53.49%)
7.43M
FLNCFluence Energy Inc
US$ 6.995
(-46.48%)
53.39M
BLACBellevue Life Sciences Acquisition Corporation
US$ 6.31
(-42.32%)
57.15k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 6.57
(-41.86%)
40.26k
CMCOColumbus McKinnon Corporation
US$ 20.885
(-41.14%)
4.57M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.090449
(31.09%)
1.12B
CYNCYNGN Inc
US$ 0.1605
(-13.10%)
922.9M
OCEAOcean Biomedical Inc
US$ 0.1999
(35.07%)
562.11M
OMGAOmega Therapeutics Inc
US$ 0.1916
(77.41%)
319.92M
INABIN8bio Inc
US$ 0.2951
(9.26%)
226.83M

ANAB Discussion

View Posts
tw0122 tw0122 4 hours ago
ANAB $16.49 + 33% ...  will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT....
👍️0
Monksdream Monksdream 5 months ago
ANAB definite uptrend
👍️0
gfp927z gfp927z 3 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
👍️0
HighPeaks HighPeaks 3 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
👍️0
tedpeele tedpeele 3 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
👍️0
HighPeaks HighPeaks 3 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
👍️0
TFMG TFMG 5 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


👍️0
LoveItInBishop LoveItInBishop 5 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
waterchaser waterchaser 5 years ago
LOL! Twitter PnD. Buyer beware.
👍️0
420man 420man 5 years ago
Once the real bounce starts it will be fast....
👍️0
Crazy Money Crazy Money 5 years ago
$10 to da moon
👍️0
420man 420man 5 years ago
This will bounce..... 15 AH
👍️0
RJ Trotts RJ Trotts 5 years ago
trying to bounce back over $11, hoping for more
👍️0
TaxiCaT TaxiCaT 5 years ago
Ouch -
👍️0
celle celle 6 years ago
Nothing happen here?
👍️0
manny371 manny371 7 years ago
This stock is making noise! Bought in Sept $ANAB
👍️0

Your Recent History

NASDAQ
ANAB
AnaptysBio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads